Get started

China

BRQS 5G Automobile and EV Smart Cockpit Market playBorqs Technologies is a global provider of 5G wireless solutions, Internet of Things (IoT) solutions, and innovative clean energy with operations in the United States, India and China. Borqs Technologies has entered into a five year Strategic Cooperation Agreement with Cheyin Intelligent Technologies, an intelligent vehicle solutions provider for automobile OEMs, to develop manufacturing of In-Vehicle-Infotainment systems, intelligent cockpit systems and intelligent assisted driving systems. Depending on the development, this stock can go to $1.9 i think.
BLong
by TopgOptions
1
Xiaomi bottomed - We are heading towards new All-time highs!Hey Investor, please see my current idea on the Xiaomi stock, where my count suggests a possible bottom for a trend reversal in order to make new highs. This is calculated based on my Elliot Waves Count by the fact, that wave C has the same length as wave a. I have checked the inner structure of wave C in order to check the inner structure of this wave. Based on this knowledge I am very confident that we might have our bottom here. Let me know what you think. This is no financial advice, just my technical view. RT
HKEX:1810
by RT_Trading_
1
Set Alerts for these linesThe art of catching a fallen knife takes lots of patience. The best time to buy a falling stock is when it starts reversing, and for that you need to have at least 2 confirmation levels for NIO to break. Before buying in NIO, you would need it to break the resistance trend line CONFIRMATION 1. Then for a strong trend reversal confirmation you need NIO to break the resistance line CONFIRMATION 2. Draw these 2 lines and set alerts for them. Let the trade come to you, don't chase the trade!
NYSE:NIO
by MoonBets
6
Hello Group lost big support levelThis stock has been slashed over this year. It has lost an important support level and it's following the same trend as other companies such as Robinhood, Bumble, Victoria's Secret, Vimeo or Deliveroo + the Chinese Crisis. We expect someday a trend reversal, so for now we recommend to place price alerts. Key level, the weekly resistance line (at $12 per share - a good one for selling-short). Moreover, it's not a bad entry for swing traders with stop loss on last lows, as a bullish divergence on the daily chart is almost complete.
NASDAQ:MOMO
by alvaromroo
1
GXC still BEarishWeekly GXC chart looks bearish with technicals and candlestick ending with a sandwich like stack with a lower low and lower close. The downside support target appears to be quite a way off, about 10% down from current. Daily chart (right) is at a previously marked Buy Zone, but MACD is pushing down more. Price now has a gap resistance to close. Let's see if it can work that out. Meanwhile, very obvious that a lower low is indicating more momentum to downside than not. I like GXC... but seems that it is not yet.
AMEX:GXC
by Auguraltrader
NIO Day 2021: Here's Everything You Need to KnowThe new vehicle targets Model 3. NIO held NIO Day 2021, its most important annual event, today in Shanghai's neighboring city of Suzhou to unveil the company's future plans and the highly anticipated new sedan, the ET5. The following is a live text update from CnEVPost based on content obtained at the event. William Li, founder, chairman and CEO of NIO, began by unveiling the company's plans for global expansion, saying NIO will enter Germany, the Netherlands, Sweden and Denmark next year. The company has already entered Norway, NIO's first stop in overseas markets, and opened its first overseas NIO House in Oslo in October. NIO aims to serve users in more than 25 countries and regions worldwide by 2025, Li said. NIO plans to have more than 1,300 battery swap stations, more than 6,000 supercharging piles and more than 10,000 destination charging piles in China by the end of 2022. NIO has provided more than 5.5 million battery swap services to customers, an average of 20,000 services per day. NIO announced the launch of Clean Parks, an ecological co-building program, and will invest CNY 100 million over the next three years to support the use of electric vehicles and the construction of clean energy infrastructure in nature reserves around the world. NIO's flagship sedan, the ET7, which has over 20 new features and enhancements in production, will begin locking in orders on January 20, with deliveries starting on March 28. The company's new mid-size sedan, the NIO ET5, was officially announced, featuring NIO's supercar DNA and a concept designed for autonomous driving. The length, width and height of the NIO ET5 are 4,790, 1,960 and 1,499 mm respectively, with a wheelbase of 2,888 mm. The ET5 is NIO's first model with an all-glass roof and is available in up to nine body colors. It is equipped with the same LiDAR configuration as the NIO ET7, with the component placed on the roof. The ET5 comes standard with NIO's super sensing system Aquila, as well as the super computing platform ADAM and frameless electric suction doors. NIO's latest autonomous driving technology, NAD (NIO Autonomous Driving), will also be available on the ET5. The full functionality of NAD will be available in a monthly subscription model, ADaaS (AD as a Service), with a service fee of CNY 680 per month, which will be provided gradually upon completion of development and validation. The interior of ET5 is similar to that of NIO ET7, providing an instrument screen as well as a central control screen. The lighting effects inside the car can follow the rhythm of the sounds. The ET5 will be equipped with AR/VR technology, and NIO has developed exclusive AR glasses with Nreal, an AR manufacturer invested by NIO Capital, which can project a 6-meter vision distance. NIO has also developed NIO VR glasses, the world's first automotive-specific high-performance VR device, in collaboration with NOLO, a VR technology company invested by NIO Capital. The ET5 uses a dual-motor intelligent four-wheel drive system with a 0-100 km/h acceleration time of 4.3 seconds and a braking distance of 33.9 meters from 100 km/h to zero. The ET5 with a 75kWh standard range battery pack has a CLTC range of over 550km. The ET5 with the 100kWh long range battery pack has a range of over 700km. The ET5 with the 150kWh extra-long range battery pack has a range4 of over 1,000km. The ET5 with the 75kWh battery pack is priced at CNY 328,000 before subsidies and CNY 386,000 for the 100kWh battery pack version. Consumers who use NIO's battery rental service BaaS will see the pre-subsidy price of the ET5 with the 75kWh pack reduced by CNY 70,000 to CNY 258,000, with a monthly battery rental fee of CNY 980. Under BaaS, the pre-subsidy price of ET5 with 100 kWh battery pack will be reduced by CNY 128,000 to CNY 258,000, and the monthly battery rental fee will be CNY 1,480. The NIO ET5 is available for pre-order now and will open for delivery in September 2022. This article was first published by Phate Zhang on CnEVPost, a website focusing on new energy vehicle news from China.
NYSE:NIO
by EqualOcean
JD.com's Healthcare Unit Prepare for Next Battle Affected heavily by recent technological advancements, the sector may soon attract Chinese regulators' attention. Background 2021 turned out to become a positive year for China's healthcare industry, where the gigantic demand stems from the aging population, growing individual wealth, and – more importantly – the COVID-19 crisis' aftermath. The market has grown consistently; in 2020, the growth rate slumped to 7.2% due to the massive lockdowns, although it is expected to rise back to 17.6% in 2021 with a total market size of CNY 8.7 trillion. Despite this, the market remains relatively undeveloped – since 2016, the Chinese authorities have been working on creating a CNY 16 trillion healthcare ecosystem by 2030. Online healthcare is in the limelight The pandemic challenged people's sense of well-being and facilitated their desire and determination to become more active and engaged in managing their health, which also boosted the need for remote medical consultations and online medicine sales. According to Deloitte, the portion of consumers who have used virtual visits rose from 15% to 19% from 2019 to early 2020, then jumped to 28% in April 2020. In fact, consumers plan to continue using the – 80% of the Deloitte survey respondents are likely to keep using other online services even post COVID-19. Jessica Tan, co-CEO of Ping An Group, once said that around 20% to 25% of healthcare services in China could be moved to the online space. This will present new opportunities to the most competitive businesses in this field. Among these, JD Health (6618:HK) and Alibaba Health (0241:HK) are two tech giant-backed companies that have ridden this surging wave quite well. The latecomer, JD Health, is moving really fast – only four months' independent operation since May 2019 before it filed a public offering. In August 2020, JD Health ranked 35th on Hurun Global Unicorn Index 2020 with a valuation at CNY 50 billion, which crowned it as the world's youngest unicorn. Different from traditional platforms, JD Health has established various online and offline integrated businesses, including JD Pharmacy, JD Health Internet Hospital and Pharmacy Alliance. How does JD.com compare in healthcare endeavors? Financial performance In September 2021, JD Health released its interim financial report with relatively strong results. Its total revenue increased by over half (55.4%), from CNY 8.8 billion in H1 2020 to CNY 13.6 billion in H1 2021, which was primarily due to the increase in revenue from sales of pharmaceutical and healthcare products within the reporting period. In fact, this continuous upward trend also shows in its gross profit for the past four fiscal years, although the loss enlarged even further in 2020 when compared with the previous years. Another catalyst for the growth could be the increase in JD Health's number of Annual Active User (AAU) accounts. As of June 30, 2021, the AAUs in the past 12 months reached 109 million, representing a net addition of over 18.8 million as compared with that of 2020. The growing number also shows that the stickiness of users has been well improved as well as its brand awareness. In other words, JD Health's constant investment in marketing activities – its selling and marketing expenses almost doubled for two consecutive fiscal years – finally began to work. JD's supply chain infrastructure casts its core barrier Although JD Health is relatively inferior to its competitor in terms of annual active users – 109 million as of June 30, 2021 – JD Health's revenue is all the way higher than that of its closest competitor, Alibaba Health, more specifically, the revenue as nearly two times higher. One booster is its complete business structure. Integrating B2B/B2C/O2O businesses, JD Health can have more wings – for example, along with the retail pharmacy, JD Health also offers its own family doctor services, online hospital services as well as smart healthcare solutions. Through the integration of pharmaceutical retail businesses and online healthcare services, the medical products users also become target customers for other consumption healthcare units, and vice versa; a closed cycle hence is developed and can also be seen in its ever-growing operating income at a CAGR of 11%. JD Logistics is another catalyst supporting the healthcare unit's strong performance, being one of the leading supply chain players in the field of medicine now. Through JD Logistics, JD Health is able to connect with upstream, midstream and downstream enterprises: from industrial enterprises and healthcare institutions to offline pharmacies and dental clinics. This absolute advantage over comparable companies enables JD Health to further cut its fulfillment costs to around 10% of total revenue, which is related to warehousing, logistics and customer service expenditures incurred by the self-operated pharmaceutical business. Future in the mist The future won't be easy for both Alibaba Health and JD Health, as the competition is intensifying. Except for the 'peer pressure,' some inherent problems exist in the essence of most healthcare services – those are mainly related to professionalism, trust and quality. It is partly because of the particularity of healthcare services and pharmaceutical drugs along with the recent market chaos, the government has tightened supervision increasingly, more than ever before. Rory Green, a China economist at TS Lombard, said that the healthcare sector is the only one not hit by regulatory scrutiny yet but is particularly vulnerable, which may possibly make it the next target. For the full article with the charts, please visit the original link.
HKEX:6618
by EqualOcean
Alibaba Healthcare Units Prepares for Next Battle in HealthcareAffected heavily by recent technological advancements, the sector may soon attract Chinese regulators' attention. Background 2021 turned out to become a positive year for China's healthcare industry, where the gigantic demand stems from the aging population, growing individual wealth, and – more importantly – the COVID-19 crisis' aftermath. The market has grown consistently; in 2020, the growth rate slumped to 7.2% due to the massive lockdowns, although it is expected to rise back to 17.6% in 2021 with a total market size of CNY 8.7 trillion. Despite this, the market remains relatively undeveloped – since 2016, the Chinese authorities have been working on creating a CNY 16 trillion healthcare ecosystem by 2030. Online healthcare is in the limelight The pandemic challenged people's sense of well-being and facilitated their desire and determination to become more active and engaged in managing their health, which also boosted the need for remote medical consultations and online medicine sales. According to Deloitte, the portion of consumers who have used virtual visits rose from 15% to 19% from 2019 to early 2020, then jumped to 28% in April 2020. In fact, consumers plan to continue using the – 80% of the Deloitte survey respondents are likely to keep using other online services even post COVID-19. Jessica Tan, co-CEO of Ping An Group, once said that around 20% to 25% of healthcare services in China could be moved to the online space. This will present new opportunities to the most competitive businesses in this field. Among these, JD Health (6618:HK) and Alibaba Health (0241:HK) are two tech giant-backed companies that have ridden this surging wave quite well. Alibaba (BABA:NASDAQ) is deemed to be the first explorer among Chinese tech giants, having joined the game as early as 1998 by founding Alibaba Health (0241:HK). In fact, it is the first Chinese Internet-healthcare company to go public on the Hong Kong Stock Exchange. Alibaba Health is primarily engaged in the pharmaceutical direct sales business, the pharmaceutical e-commerce platform business, medical and healthcare services platforms and digital infrastructure business and related services, though it wants to take off the 'e-pharmacy' tag for long. How does Alibaba compare in the healthcare endeavors? Financial Performance Alibaba Health finally became fully profitable in its fiscal 2021, when the revenue reached CNY 15.52 billion Among four major businesses, medicine remains the main contributor to its revenue, amounting to CNY 13.21 billion, or about 85% of the total revenue. The rest is contributed by pharmaceutical e-commerce platform business, the medical health service business and digital infrastructure business, with revenues of CNY 1.96 billion, CNY 284 million and CNY 53 million respectively. Benefiting from the improving cost control ability and the emerging economies of scale, the overall expenses of Alibaba Health are far less than that of JD Health for every comparable fiscal year. BABA's backing is the ace card of Alibaba Health As the healthcare business arm of Alibaba Group, the natural traffic comes with related brand benefits; Alibaba Health's core pharmaceutical direct sales and e-commerce platform businesses are thus boosted to a great extent. Three specific edges are worth mentioning. First, brand power drives growth. In 2021, Alibaba has grown its brand value by 32% year-on-year to USD 201.86 billion, with a 2nd ranking domestically and 7th ranking globally. As one of the most valuable brands, consumers are more likely to pay a value premium for the products with this recognizable name, or for the creditability it owns. This is indeed what is going on with Alibaba Health. For the 12 months ended March 31, 2021, the revenue from drugs generated from the pharmaceutical direct sales business under the brand of 'Alibaba Health' increased by 86.1% year-on-year, accounting for 64.8% of the revenue of the business. And the number of annual active users of the direct online stores in the reporting period reached a record high of 81 million. Second, synergistic benefits of Alibaba's ecosystem. The synergy effect is most difficult or even impossible to be imitated by competitors. When looking back at Alibaba's business scope, we could see it has already laid out a lot – Alipay's insurance services and 'Future Hospital' plan, O2O medicine delivery service on takeaway platform and hospital-specialized modules on DingTalk – most major businesses owned by Alibaba have medical-related s. With continuous investment in these business-to-consumer marketplace made by the Group, Alibaba Health is able to enhance health awareness and acquire new customers at relatively low acquisition costs, which lays a strong foundation for future growth. As of March 31, 2021, the number of annual active users had exceeded 280 million on Tmall's Pharmaceutical Platform while Alipay's healthcare channel as a whole reached over 520 million annual active users for the fiscal year. Third, empowerment of big data. As a wholly-owned subsidiary of Alibaba with deep roots in the Internet, Alibaba Health's capabilities and resources are naturally geared towards leveraging the prowess of the Internet, big data and Cloud computing. To further boost its digital infrastructure business, for example, tracking platform 'Ma Shang Fang Xin' and digital health business, Alibaba Health has been working closely with Alibaba Cloud to lead the healthcare area. In addition, it also focuses on digital infrastructure. Based on the Group's internal AI, big data, payment and IT capabilities, Alibaba Health is working on exploring the construction of intelligent medical systems, such as AI-assisted diagnostic decision-making, remote imaging platforms and blockchain data security solutions in major hospitals and regions. Future in the mist The future won't be easy for both Alibaba Health and JD Health, as the competition is intensifying. Except for the 'peer pressure,' some inherent problems exist in the essence of most healthcare services – those are mainly related to professionalism, trust and quality. It is partly because of the particularity of healthcare services and pharmaceutical drugs along with the recent market chaos, the government has tightened supervision increasingly, more than ever before. Rory Green, a China economist at TS Lombard, said that the healthcare sector is the only one not hit by regulatory scrutiny yet but is particularly vulnerable, which may possibly make it the next target. For the full article with the charts, please visit the original link.
HKEX:241
by EqualOcean
A Spectacular Dip Buy Chinese Stock Exchange Chinese #FXI Large Cap ETF ready for a dip buy around here and I will be watching for the triangle to breakout above the red line. Here are the top 15 holding of the ETF: Symbol Holding % Assets 3690 Meituan Class B 9.51% 700 Tencent Holdings Ltd. 9.08% 9988 Alibaba Group Holding Ltd. 7.49% 939 China Construction Bank Corporation Class H 5.92% 9618 JD.com, Inc. Class A 5.39% 2318 Ping An Insurance (Group) Company of China, Ltd. Class H 4.21% 1398 Industrial and Commercial Bank of China Limited Class H 4.11% 9888 Baidu, Inc. Class A 4.06% 2269 Wuxi Biologics (Cayman) Inc. 4.02% 1810 Xiaomi Corp. Class B 3.39% 1211 BYD Company Limited Class H 3.31% 9999 NetEase, Inc 3.29% 3968 China Merchants Bank Co., Ltd. Class H 3.05% 3988 Bank of China Limited Class H 2.69% 2382 Sunny Optical Technology (Group) Co., Ltd. 1.92%
AMEX:FXILong
by bartuclk
1
China Evergrande Defaults! Now What?China Evergrande, the second-largest real estate developer in China, has been narrowly dodging default for months. The Company has more than US $300 billion in debt that, as it warned the market back in September, it believed would be difficult for it to service. (As an aside, it is believed that China Evergrande could have an additional US $150 billion in debt, off its official financial books). Put simply, the cash flow of the Company, severely dampened by the cooling Chinese housing market, is not enough for it to service interest payments to those from which it borrowed funds, typically in the form of interest-bearing corporate bonds. One such unlucky purchaser of China Evergrande corporate bonds, among others, are off-shore investors. Off-shore bondholders will likely be the least prioritised of the Company’s investors when receiving interest payments or reparations. China Evergrande defaults! Perhaps fortuitously, it was the failure by China Evergrande to make interest payments to this very group of investors that prompted Fitch Ratings to upgrade the Company’s status to “restricted default” on December 9. Interestingly, China Evergrande is the twelfth Chinese real estate firm to default on bonds in 2021, and by far the largest to do so. Now what? Other rating agencies, such as Moody’s and S&P Global, have not been so quick to upgrade their status of China Evergrande. However, S&P Global has noted that China Evergrande’s default is “inevitable”. China Evergrande themselves seem to be ignoring public comment on its failure to meet its obligation, nor has it ceased operations or begun any formal paperwork to address its potential bankruptcy. China Evergrande is currently under restructuring while attempting to continue operations as usual. The restructuring includes renegotiating its liabilities and offloading non-construction arms of the Company at bargain prices such as its property management business, as well as stakes in a major Chinese bank and (strangely enough) a streaming services. Pressure is being applied to the Company’s leaders to speed up its restructuring since the change in its Fitch rating. According to Bloomberg, the China Evergrande restructure is being heavily monitored, if not outright controlled by Chinese Authorities in Beijing and the Company’s home province of Guangdong. Right now, the official line from the Central Bank of China is that the China Evergrande crisis is being handled as per the “principles of marketization and rule of law,”. If more rating agencies follow Fitch Rating in the coming weeks, China Evergrande could slip into something a little more serious than restricted default and the above quote may become a little truer, with Chinese authorities being hamstrung in their ability to interfere with a meltdown.
HKEX:3333
by BlackBull_Markets
$BABA sniper edition #1*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Recap: My team started a long $BABA position November 18, 2021 at $161 per share. My team averaged down on our position today at $122 per share bringing our share average to $141.5. Our First Entry: $161 Our 2nd Entry: $122 Take Profit 1: $180 Take Profit 2: $193 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NYSE:BABALong
by SimplyShowMeTheMoney
8